Dr. Govind Warrier is an oncology physician-scientist at the Johns Hopkins Kimmel Cancer Center, where he blends clinical care with cutting-edge research. Specializing in immunotherapy, he investigates how immune checkpoint inhibitors like anti–PD-1 and anti–LAG-3 therapies can be used to treat difficult cancers, including skin cancers such as basal cell carcinoma. As a co-leader of a recent study, he has pushed for moving these drugs earlier in treatment, believing that unlocking the immune system’s potential can lead to more durable and effective cancer control.